Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.

ABSTRACT:

Abstract

In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.

SUBMITTER: Qualls DA 

PROVIDER: S-EPMC10797539 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature